Method For Using Composition With Enhanced Passenger Molecule Loading

ABSTRACT

A composition comprising surfactant-enhanced phospholipid vesicles with one or more cannabinoid substance encapsulated therein is disclosed, wherein one or more surfactant is utilized for enhancing loading and increasing encapsulation efficiency of cannabinoid passenger molecules within phospholipid structures. A method is disclosed for making a surfactant-enhanced phospholipid vesicles with one or more cannabinoid substance encapsulated therein, wherein one or more surfactant is used for enhancing loading and increasing encapsulation efficiency of passenger molecules in phospholipid structures. A method of using surfactant-enhanced phospholipid vesicles with one or more cannabinoid substance encapsulated therein is disclosed wherein one or more surfactant enhances loading and increases encapsulation efficiency of cannabinoid substances in phospholipid structures. A composition and method of making surfactant-enhanced phospholipid vesicles with one or more lipophilic passenger substance encapsulated therein is disclosed wherein one or more surfactant is utilized for enhancing loading and increasing encapsulation efficiency of passenger molecules within phospholipid structures.

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application Nos.62/779,797 filed Dec. 14, 2018, and 62/890,940, filed Aug. 23, 2019,which are incorporated by reference into this utility patentapplication.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

Not applicable.

TECHNICAL FIELD OF INVENTION

This invention relates to the field of using surfactants to enhanceencapsulation of lipophilic passenger molecules in nano-sizedphospholipid structures.

BACKGROUND OF THE INVENTION

Active components have been sequestered in phospholipid particles usingprior art methods and compositions, but these known prior art methodsand compositions fail to retain all types of active components,especially at higher concentrations, in a solubilized state for extendedperiods of time, which decreases the overall stability and usability ofthe preparations.

For instance, known nanolipid particle prior art, U.S. Pat. Nos.8,597,678; 8,545,574; 8,545,575; 9,480,650; 9,364,434; 9,399,015; andU.S. Pat. No. 9,897,234, to Fountain, fail to solve the present problemof precipitation for certain types of lipophilic passenger molecules.Moreover, these Fountain prior art references rely on aqueous-dilutedformulations using an aqueous phase to close the particles with thepassenger molecules encapsulated within the particles, which is believedto contribute to the precipitation problem for certain lipophilicpassengers. So, it has been found that for certain lipophilic passengermolecules, such aqueous-diluted nano-lipid formulations are only stablefor up to three days using the prior art methods and compositions.Certain lipophilic passengers crystallize out of solution and settle tothe bottom of the formulation rendering the formulation usable for onlythe first day or two after preparation. This precipitation necessitatespreparation of materials at the point of use and in small batchquantities over the course of multiple days, presenting logisticaldifficulties in the preparation and use of uniform materials for studyor administration. And, formulations prepared at point of use aretotally inadequate for large-scale use, which prevents a wider use ofthese lipophilic passengers in lipid particles.

What is needed is a method and composition that solves the precipitationproblem and improves the physical stability of the lipophilic passengerformulations over extended shelf-life periods of time, thereby allowingfor advance preparation of a stable formulation of lipophilicpassengers.

SUMMARY OF THE INVENTION

In the following manner, the problems encountered by the prior artsystems, including Fountain, have been solved. Disclosed herein is anovel method of encapsulating lipophilic passenger molecules insurfactant-enhanced phospholipid vesicles utilizing one or moresurfactants as an encapsulating agent, rather than water, to prepare apassenger encapsulate having surfactant-enhanced phospholipid vesicleswith lipophilic passengers encapsulated therein. Disclosed herein arecompositions of surfactant-enhanced phospholipid vesicles withencapsulated lipophilic passengers, methods of makingsurfactant-enhanced phospholipid vesicles with encapsulated lipophilicpassengers, and methods of using surfactant-enhanced phospholipidvesicles with encapsulated lipophilic passengers. The claimedsurfactant-enhanced phospholipid vesicles have up to 25% (w/w)surfactant and less than 2% (w/w) water. In the surfactant-enhancedphospholipid vesicles prepared according to the present invention, thepassenger molecules remain encapsulated in the vesicles even whenpassenger encapsulate is combined or diluted with excipient ingredientsor water in a preparation for administration to a subject.

Compositions are disclosed with enhanced loading of passenger moleculesin phospholipid based vesicles utilizing a surfactant to increase theencapsulation concentration of passenger molecules while decreasingprecipitation of the encapsulated passenger. The surfactant enhancersare especially efficacious for increasing encapsulation of lipophilicpassenger molecules in the phospholipid vesicles. Passenger moleculesthat may benefit from enhanced encapsulation include, but are notlimited to, cannabinoids, cannabidiol (CBD), tetrahydrocannabinol (THC),menthol, lidocaine, aspirin, ibuprofen, acetaminophen, antifungals, andretinoids. Of particular interest as passengers are cannabinoids, suchas cannabidiol (CBD) and tetrahydrocannabinol (THC). Cannabinoids can benaturally derived from botanical sources, such as Cannabis sativa orCannabis indica, including marijuana and/or hemp varieties, or can besynthetically-derived.

Cannabinoids are a class of typically lipophilic substances that, aspassenger molecules, benefit from enhanced loading in phospholipid basedstructures with the use of surfactants. Utilizing surfactant enhancementallows for a substantial increase in the concentration of cannabinoidcompounds that can be encapsulated as passengers in the phospholipidvesicles. When surfactants are used to enhance encapsulation ofcannabinoid passengers, the preparation remains stably encapsulated andprecipitation of the cannabinoids does not occur even at very highconcentrations. The enhancements are achieved for both lipophiliccannabinoid substances and hydrophilic cannabinoid substances, such ascrystalline CBD. Cannabinoid encapsulates having surfactant-enhancedphospholipid vesicles with one or more cannabinoid encapsulated thereincan be advantageously used to administer cannabinoids to a subject byoral, transmucosal, or transdermal routes. Once the cannabinoidpassenger is fully encapsulated, the cannabinoid encapsulate can bediluted to the desired dosage without precipitation of the cannabinoidfrom the preparation.

Disclosed herein is a method of making surfactant-enhanced phospholipidvesicles encapsulating one or more cannabinoid. The method comprises thesteps of providing one or more cannabinoid substance; providing aphospholipid stock solution having phospholipids, ethanol and water,where water comprises 5% or less by weight of the phospholipid stocksolution; diluting the phospholipid stock solution with a quantity ofethanol to produce an ethanol-diluted phospholipid stock, combining thecannabinoid with the ethanol-diluted phospholipid stock to produce acannabinoid-phospholipid stock; and mixing the cannabinoid-phospholipidstock with a surfactant. A cannabinoid encapsulate results having one ormore surfactant-enhanced phospholipid vesicle encapsulating one or morecannabinoid substance therein, with the cannabinoid encapsulate havingless than 2% water (w/w).

Surfactants useful in the method are Polysorbates, Polysorbate (Tween)20, Polysorbate (Tween) 80, PEG esters of hydrogenated castor oil,PEG-40 hydrogenated castor oil, Polyethylene Glycols, Ethoxylated etheralcohols, Propylene Glycols, PPG esters, Sodium, Potassium or AmmoniumSalts of Fatty Acids, and derivatives or combinations thereof.Optionally, the surfactant is Polysorbates and derivatives, PEG estersof hydrogenated castor oil and derivatives, and combinations thereof.Optionally, the surfactant is Polysorbate (Tween) 20, Polysorbate(Tween) 80, PEG-40 hydrogenated castor oil, and combinations thereof.The surfactant comprises up to 25% of the cannabinoid encapsulate.Optionally, the surfactant is 0.5% to 20% of the cannabinoidencapsulate.

Passenger molecules useful for the invention are synthetically-derivedcannabinoids or cannabinoid and non-cannabinoid substances derived fromCannabis spp., primarily Cannabis sativa and Cannabis indica. Among theknown Cannabis-derived substances that may be used for the invention areCannabidiol (CBD), Tetrahydrocannabinol (THC), Cannabigerol (CBG),Cannabidiolic Acid (CBDA), Tetrahydrocannabinolic Acid (THCA),Cannabinol (CBN), Cannabichromene (CBC), Cannabicyclol (CBL),Cannabivarin (CBV), Tetrahydrocannabivarin (THCV), Cannabidivarin(CBDV), Cannabichromevarin (CBCV), Cannabigerovarin (CBGV), Cannabigerolmonomethyl ether (CBGM), Cannabielsoin (CBE), Cannabicitran (CBT),Cannabis-derived terpenes, Cannabis-derived flavonoids, whole plantextracts of Cannabis sativa or Cannabis indica, and combinationsthereof. Optionally, the Cannabis-derived substances are cannabidiol(CBD), tetrahydrocannabinol (THC), whole plant extract of Cannabissativa, whole plant extract of Cannabis indica, and combinationsthereof. The cannabinoid encapsulate has a cannabinoid concentration of3 mg/mL to 300 mg/mL.

A phospholipid stock solution useful for the method has phospholipids,ethanol and water, wherein water is 5% (w/w) or less of the stock.Optionally, the phospholipid stock solution has 10-20% (w/w)phospholipids, 75-89% (w/w) ethanol, and 1-5% water (w/w). Thephospholipid stock solution is diluted with a quantity of ethanol up to75% (w/w) prior to addition of or in combination with the cannabinoidpassenger substance.

Also disclosed is a composition of surfactant-enhanced phospholipidvesicles with one or more cannabinoid substance encapsulated thereinprepared according to the described method. The composition comprisesone or more synthetic or botanical-derived cannabinoid substanceencapsulated in surfactant-enhanced phospholipid vesicles, thecannabinoid substance concentration being from 3.0 mg/mL to 300 mg/mL,and the surfactant-enhanced phospholipid vesicles having one or moresurfactant, phospholipids, ethanol, and water, wherein the one or moresurfactant is up to 25% (w/w) of the composition, and the water is lessthan 2% (w/w) of the composition. The surfactant is optionally,Polysorbates and derivatives, PEG esters of hydrogenated castor oil andderivatives, or combinations thereof. Optionally, the surfactant isPolysorbate (Tween) 20, Polysorbate (Tween) 80, PEG-40 hydrogenatedcastor oil, or combinations thereof. Optionally, the one or morecannabinoid substance is botanical-derived cannabidiol (CBD),tetrahydrocannabinol (THC), Cannabis-derived terpenes, Cannabis-derivedflavonoids, a whole plant extract of Cannabis sativa, a whole plantextract of Cannabis indica, and combinations thereof. Optionally, theone or more cannabinoid substance is synthetically-derived cannabidiol(CBD), tetrahydrocannabinol (THC), and combinations thereof.

Also disclosed are methods of using the composition ofsurfactant-enhanced phospholipid vesicles with one or more cannabinoidsubstance encapsulated therein. Methods of using the composition includethe steps of providing a cannabinoid encapsulate having one or moresynthetic or botanical-derived cannabinoid substance encapsulated in oneor more surfactant-enhanced phospholipid vesicles having phospholipids,ethanol, water, and one or more surfactant selected from Polysorbatesand derivatives, PEG esters of hydrogenated castor oil and derivatives,and combinations thereof, wherein the cannabinoid substance in thecannabinoid encapsulate has a concentration of 3 mg/mL to 300 mg/mL, andthe cannabinoid encapsulate has less than 2% water (w/w) and up to 25%(w/w) of the surfactant; and administering a quantity of an oralpreparation having 1 mg to 100 mg of cannabinoid substance to a subject.Optionally, the composition is delivered orally as a drinkable beverageof about 1.5-12 ounces, drinkable shot of about less than 1.5 ounce, orswish and swallow preparation of about less than 1.0 ounce. Optionally,the composition is administered transmucosally to the oral cavity of asubject as a liquid drop, liquid spray, aerosol, liquid shot, gel,paste, lozenge, gum, gummy candy, hard candy, orally dissolving strip,tablet, or swish and swallow preparation. Optionally, the composition isadministered topically or transdermally to the epidermis of a subject asa cream, lotion, ointment, wax, topically applied spray, gel, balm, ortransdermal patch.

The preparations for oral, transmucosal, topical, and transdermaldelivery may further comprise one or more excipient ingredients suitablefor a preparation delivered orally, transmucosally, topically, ortransdermally wherein the excipient ingredients are for stabilization,appearance, flavoring, or dilution of the preparation. The oral,transmucosal topical, or transdermal preparations may further compriseone or more sweeteners, flavorings, vitamins, minerals, herbalingredients and extracts, fruit extracts, vegetable extracts, spices orspice extracts, caffeine, amino acids, or nutraceutical ingredients.

DETAILED DESCRIPTION

Disclosed herein are Surfactant-Enhanced Phospholipid Vesicles (SEPV),which are nano-sized phospholipid vesicles that employ a surfactant tocomplete the encapsulation process for lipophilic passenger substances,which enhances the encapsulation efficiency and prevents precipitationof the passenger molecules.

Disclosed herein is a method of making surfactant-enhanced phospholipidvesicles encapsulating one or more cannabinoid or Cannabis spp.-derivedsubstance. The method comprises the steps of providing one or morecannabinoid or Cannabis spp.-derived substance; providing a phospholipidstock solution having phospholipids, ethanol and water, where watercomprises 5% or less by weight of the phospholipid stock solution;diluting the phospholipid stock solution with a quantity of ethanol toproduce an ethanol-diluted phospholipid stock, combining the cannabinoidor Cannabis spp.-derived substance with the ethanol-diluted phospholipidstock to produce a cannabinoid-phospholipid stock; and mixing thecannabinoid-phospholipid stock with a surfactant. A cannabinoidencapsulate results having one or more surfactant-enhanced phospholipidvesicle encapsulating one or more cannabinoid or Cannabis spp.-derivedsubstance therein, with the cannabinoid encapsulate having less than 2%water (w/w).

Also disclosed is a composition of surfactant-enhanced phospholipidvesicles with one or more cannabinoid or Cannabis spp.-derived substanceencapsulated therein prepared according to the described method. Thecomposition comprises one or more cannabinoid or Cannabis spp.-derivedsubstance encapsulated in surfactant-enhanced phospholipid vesicles, thecannabinoid or Cannabis spp.-derived substance concentration being from3.0 mg/mL to 300 mg/mL, and the surfactant-enhanced phospholipidvesicles having one or more surfactant, phospholipids, ethanol, andwater, wherein the one or more surfactant is up to 25% (w/w) of thecomposition, and the water is less than 2% (w/w) of the composition. Thesurfactant is optionally, Polysorbates and derivatives, PEG esters ofhydrogenated castor oil and derivatives, or combinations thereof.Optionally, the surfactant is Polysorbate (Tween) 20, Polysorbate(Tween) 80, PEG-40 hydrogenated castor oil, or combinations thereof.Optionally, the one or more cannabinoid or Cannabis spp.-derivedsubstance is Cannabis sativa-derived cannabidiol (CBD), Cannabissativa-derived tetrahydrocannabinol (THC), Cannabis sativa-derivedterpenes, Cannabis sativa-derived flavonoids, a whole plant extract ofCannabis sativa-derived substance, and combinations thereof. Optionally,the one or more cannabinoid or Cannabis spp.-derived substance isCannabis indica-derived cannabidiol (CBD), Cannabis indica-derivedtetrahydrocannabinol (THC), Cannabis indica-derived terpenes, Cannabisindica-derived flavonoids, a whole plant extract of Cannabisindica-derived substance, and combinations thereof. Optionally, the oneor more cannabinoid substance is a synthetically-derived cannabinoid,synthetically-derived cannabidiol (CBD), synthetically-derivedtetrahydrocannabinol (THC), and combinations thereof

Also disclosed are methods of using the composition ofsurfactant-enhanced phospholipid vesicles with one or more cannabinoidor Cannabis spp.-derived substance encapsulated therein. The method ofusing the composition includes the steps of providing a cannabinoidencapsulate having one or more cannabinoid or Cannabis spp.-derivedsubstance encapsulated in one or more surfactant-enhanced phospholipidvesicles having phospholipids, ethanol, water, and one or moresurfactant selected from Polysorbates and derivatives, PEG esters ofhydrogenated castor oil and derivatives, and combinations thereof,wherein the cannabinoid or Cannabis spp.-derived substance in thecannabinoid encapsulate has a concentration of 3 mg/mL to 300 mg/mL, andthe cannabinoid encapsulate has less than 2% water (w/w) and up to 25%(w/w) of the surfactant; and administering a quantity of the oralpreparation having 1 mg to 100 mg of cannabinoid or Cannabisspp.-derived substance to a subject. Optionally, the composition isdelivered orally or transmucosally to a subject. Optionally, thecomposition is delivered orally as a drinkable beverage of about 1.5-12ounces, drinkable shot of about less than 1.5 ounce, or swish andswallow preparation of about less than 1.0 ounce. Optionally, thecomposition is administered transmucosally to the oral cavity of asubject as a liquid drop, liquid spray, aerosol, liquid shot, gel,paste, lozenge, gum, gummy candy, hard candy, orally dissolving strip,tablet, or swish and swallow preparation. Optionally, the composition isadministered topically or transdermally to the epidermis of a subject.Optionally, the composition is administered topically or transdermallyto the epidermis of a subject as a cream, lotion, ointment, wax,topically applied spray, gel, balm or transdermal patch.

Surfactants useful in the method are Polysorbates, Polysorbate (Tween)20, Polysorbate (Tween) 80, PEG esters of hydrogenated castor oil,PEG-40 hydrogenated castor oil, Polyethylene Glycols, Ethoxylated etheralcohols, Propylene Glycols, PPG esters, Sodium, Potassium or AmmoniumSalts of Fatty Acids, and derivatives or combinations thereof.Optionally, the surfactant is Polysorbates and derivatives, PEG estersof hydrogenated castor oil and derivatives, and combinations thereof.Optionally, the surfactant is Polysorbate (Tween) 20, Polysorbate(Tween) 80, PEG-40 hydrogenated castor oil, and combinations thereof.The surfactant comprises up to 25% of the cannabinoid encapsulate.Optionally, the surfactant is 0.5% to 20% of the cannabinoidencapsulate.

Passenger molecules useful for the invention are synthetically-derivedcannabinoids or cannabinoid and non-cannabinoid substances derived fromCannabis spp., primarily Cannabis sativa and Cannabis indica. Among theknown Cannabis-derived substances that may be used for the invention areCannabidiol (CBD), Tetrahydrocannabinol (THC), Cannabigerol (CBG),Cannabidiolic Acid (CBDA), Tetrahydrocannabinolic Acid (THCA),Cannabinol (CBN), Cannabichromene (CBC), Cannabicyclol (CBL),Cannabivarin (CBV), Tetrahydrocannabivarin (THCV), Cannabidivarin(CBDV), Cannabichromevarin (CBCV), Cannabigerovarin (CBGV), Cannabigerolmonomethyl ether (CBGM), Cannabielsoin (CBE), Cannabicitran (CBT),Cannabis-derived terpenes, Cannabis-derived flavonoids, whole plantextracts of Cannabis sativa or Cannabis indica, and combinationsthereof. Optionally, the Cannabis-derived substances are cannabidiol(CBD), tetrahydrocannabinol (THC), whole plant extract of Cannabissativa, whole plant extract of Cannabis indica, and combinationsthereof. The cannabinoid encapsulate has a cannabinoid concentration of3 mg/mL to 300 mg/mL.

The phospholipid stock solution useful for the method has phospholipids,ethanol and water, wherein water is 5% (w/w) or less of the stock.Optionally, the phospholipid stock solution has 10-20% (w/w)phospholipids, 75-89% (w/w) ethanol, and 1-5% (w/w) water. Thephospholipid stock solution is diluted with a quantity of ethanol up to75% (w/w) prior to addition of or in combination with the cannabinoidpassenger substance.

Compositions with enhanced loading of cannabinoid passenger aredisclosed wherein the compositions may be used as oral preparations,either alone or in conjunction with a beverage product, for oraldelivery of synthetically or botanically-derived cannabinoids or othercompounds derived from Cannabis spp. Compositions with enhanced loadingof cannabinoid passenger are also disclosed wherein the compositions maybe used as topical or transdermal preparations applied to epidermis fordelivery of synthetically or botanically-derived cannabinoids or othercompounds derived from Cannabis spp.

Phospholipid vesicles are generally sphere-shaped vesicles with one ormore phospholipid layer surrounding a core space which may containpassenger molecules sequestered therein. The vesicles can be used asdelivery vehicles for passenger molecules. Passenger molecules areactive substances that can be sequestered or encapsulated in thephospholipid vesicles for delivery of a substance to a subject. Theload-enhancing surfactant used with phospholipid vesicles as describedherein is particularly beneficial for encapsulation of passengers thatare lipophilic. Surfactants (i.e. surface-active agents) are compoundsthat are partly hydrophilic (water-soluble) and partly lipophilic(soluble in lipids or oils) and lower the surface tension (orinterfacial tension) between two liquids, between a gas and a liquid, orbetween a liquid and a solid. Surfactants are usually organic compoundsthat are amphiphilic, consisting of a hydrophilic head group and ahydrophobic tail, and they generally are suitable compounds for use incomplex mixtures. The surfactants useful for the present inventionexhibit a very low toxicity level and are acceptable for use inpharmaceuticals, cosmetics and food products.

Particular surfactants in precisely controlled amounts have been foundthat will enhance stability of passenger molecules in the phospholipidvesicles. These surfactants not only prevent precipitation of thepassenger, but also allow for increased passenger molecule loading intothe surfactant-enhanced phospholipid vesicles up to more than ahundred-fold over the previous water-based models.

Preparation of nanolipid particles typically requires the use of anaqueous phase to complete the encapsulation and close the vesicles withthe passengers sequestered therein. In the present invention, asurfactant is utilized to close the vesicles and complete theencapsulation phase. An aqueous phase is not required for preparation ofthe composition, however, after passengers are fully encapsulated in thecomposition, the final composition of surfactant-enhanced phospholipidvesicles can be advantageously combined with an aqueous-based deliverysystem without precipitation or loss of the encapsulated passengers fromthe vesicles or degradation or the vesicles.

Compositions are disclosed with enhanced loading of passenger moleculesin surfactant-enhanced phospholipid based vesicles utilizing asurfactant to increase the encapsulation concentration of passengermolecules while decreasing precipitation of the encapsulated passenger.The surfactant enhancers are especially efficacious for increasingencapsulation of lipophilic passenger molecules in the phospholipidvesicles. Passenger molecules that may benefit from enhancedencapsulation include, but are not limited to, cannabinoids, cannabidiol(CBD), tetrahydrocannabinol (THC), menthol, lidocaine, aspirin,ibuprofen, acetaminophen, antifungals, and retinoids.

Of particular interest as passengers are cannabinoids substances derivedfrom plants or synthetically-derived. Plant-derived cannabinoids may bederived from Cannabis species, including Cannabis sativa and Cannabisindica. Cannabinoids are a class of typically lipophilic substances thatas passenger molecules benefit from enhanced loading in phospholipidbased structures with the use of surfactants. Utilizing surfactantenhancement allows for a substantial increase in the concentration ofcannabinoid compounds that can be encapsulated as passengers in thephospholipid vesicles. When surfactants are used to enhanceencapsulation of cannabinoid passengers, the preparation remains stablyencapsulated and precipitation of the cannabinoids does not occur, evenat very high concentrations. The enhancements are achieved for bothlipophilic cannabinoid substances and hydrophilic cannabinoidsubstances, such as crystalline CBD, but are especially advantageous forlipophilic passenger substances.

A liquid dosage form enabling delivery of cannabidiol (CBD) usingnanolipid particle technology to encapsulate the CBD for oraladministration was utilized as part of a pharmacokinetic (PK)bioavailability study. In this aqueous-diluted formulation, crystalswere observed in stored samples within a few days of preparation of thesolution. It was found that the aqueous diluted formulation onlymaintained stability for up to three days, then the CBD crystallized outof solution, and the precipitated CBD settled to the bottom of theformulation. This precipitation necessitates preparation of materials atthe point of use and in small batch quantities over the course ofmultiple days, which presents logistical difficulties in the preparationand use of uniform materials for study or administration. Formulationsprepared at point of use are totally inadequate for large-scale use, andwould prevent a wider use of the lipophilic passengers in lipidparticles. Given these challenges, investigations were directed tofinding options for reducing or eliminating the crystallization observedin the formulation.

Initial endeavors to remediate the crystallization focused on improvingsolubility within the system and it was found that precisely controlledamounts of selected surfactants provided the desired improvements inboth stability and solubility of the passenger, which in this case wasCBD. These studies demonstrated that the precisely controlledsurfactants yielded the desired improvement in reducing crystallizationwith no crystals observed in the samples after three-months storage atroom temperature. This surfactant enhancing approach solved thechallenges seen with the aqueous-diluted formulation and represented anovel composition with enhanced encapsulation of more difficultpassenger molecules. Initiatives to develop a beverage type formulationusing a phospholipid vesicle system specifically for cannabinoids alsoled to additional research into increasing the load of cannabinoids thatcan be incorporated into an aqueous delivery vehicle without degradationof the cannabinoid encapsulate.

Investigations then focused on the maximum amount of CBD that would beencapsulated into the aqueous system and at what point of aqueousdilution did the precipitation occur. As CBD is a lipophilic moleculewith reasonable solubility in alcohol, adjunctive compounds wereinvestigated to enhance the solubility and compatibility of CBD with thephospholipid technology as well as the aqueous phase of the system. Itwas found that the amount of the passenger molecule loaded into thephospholipid structures could be increased by including specificsolubilizer compounds into the encapsulation phase, with theincorporation of certain surfactants being particularly efficacious,leading to improvements in encapsulation and remediation of thecrystallization of cannabidiol observed in the original aqueous-basedformulation used in early PK studies.

It was determined that use of these surfactants as stability-enhancingcompounds not only prevented precipitation of the CBD passenger, butalso allowed for greatly increased passenger molecule loading into thephospholipid vesicles with CBD concentrations increased more than ahundred-fold over the previous models. Using aqueous-based compositionscould only accommodate up to 1-2 mg/mL of CBD as a passenger, whereasthe enhanced system was shown to accommodate concentrations more than100 times higher than the previous system. Cannabinoids concentrationsup to 300 mg/mL are now achievable.

Surfactants are partly hydrophilic (water-soluble) and partly lipophilic(soluble in lipids, or oils) compounds that lower the surface tension(or interfacial tension) between two liquids, between a gas and aliquid, or between a liquid and a solid. Surfactants are usually organiccompounds that are amphiphilic, consisting of a hydrophilic head groupand a hydrophobic tail and they generally are suitable compounds for usein complex mixtures. The surfactants useful for the present inventionexhibit a very low toxicity level and are acceptable for use inpharmaceuticals, cosmetics and food products.

Previous work had indicated that many surfactants would causedestabilization of lipid bilayers leading to collapse of the vesicles.Indeed surfactants, such as Triton X100 (nonoxynol-9), have been usedspecifically to disrupt nanolipid particles to release the encapsulatedpassenger molecules. It was believed that any added surfactant wouldinterfere with the integrity of the lipid bilayer of the nanolipidparticles and destabilize the system, thereby causing the nanolipidparticles structures to collapse and release any encapsulated compoundinto the continuous phase of the preparation. The use of surfactantswas, therefore, not expected to be compatible with phospholipidparticles based on the original nanolipid particles development andapproach. It has surprisingly now been found that specific alternativesurfactants in precisely controlled amounts are able to advantageouslyinfluence the viability and stability of the lipid structures while alsoachieving increased encapsulation capacity and decreased precipitationof passenger molecules. When used in the method of the invention, theseprecisely controlled surfactants do not lead to collapse ordestabilization of the vesicles.

Load-enhancing surfactants useful for the present invention include, butare not limited to, Polysorbates, PEG esters of hydrogenated castor oil,Polyethylene Glycols, Ethoxylated ether alcohols, Propylene Glycols, PPGesters, Sodium, Potassium or Ammonium Salts of Fatty Acids, andderivatives and combinations thereof. Optionally, the load enhancingcompounds are PEG-40 hydrogenated castor oil and derivatives,Polysorbate (Tween) 20 and derivatives, Polysorbate (Tween) 80 andderivatives, and combinations thereof. In one embodiment of theinvention, the load-enhancing compound is a PEG ester of hydrogenatedcastor oil. In one embodiment of the invention, the load-enhancingcompound is PEG 40 hydrogenated castor oil. In one embodiment of theinvention, the load-enhancing compound is Polysorbate (Tween) 20. In oneembodiment of the invention, the load-enhancing compound is Polysorbate(Tween) 80. In one embodiment of the invention, the load-enhancingcompound is a combination of PEG 40 hydrogenated castor oil andPolysorbate (Tween) 20 or Polysorbate (Tween) 80.

Composition

As disclosed herein, Surfactant-Enhanced Phospholipid Vesicles (SEPV)are phospholipid vesicles that employ a surfactant to complete theencapsulation process for lipophilic passenger substances which enhancesthe encapsulation efficiency and prevents precipitation of the passengermolecules. The Surfactant-Enhanced Phospholipid Vesicles comprise aphospholipid stock solution having phospholipids, ethanol and water, anethanol diluent, a lipophilic passenger molecule and a load-enhancingsurfactant component.

The phospholipid stock solution has a composition ratio of 75-89%ethanol, 10-20% phospholipids and 1-5% water, (w/w). Optionally, thephospholipid stock solution has a component ratio of 80% ethanol/17.75%phospholipids/2.25% water (w/w). Optionally, the ethanol used in thephospholipid stock is dehydrated 190 proof ethanol. Optionally, thephospholipids are derived from soy lecithin. Phospholipids are selectedfrom phosphatidylcholine (PC), phosphatidylethanolamine (PE),phosphatidic acid (PA) and phosphatidylinositol (PI), and mixturesthereof. Optionally, phosphatidylcholine (PC) comprises at least 50% byweight of the phospholipid mixture. Optionally, phosphatidylcholinecomprises 65% of the phospholipid total. Optionally, the ethanol diluentis dehydrated 190 proof ethanol. Optionally, up to 75% (w/w) ethanoldiluent is added to the phospholipid stock solution prior to addition ofor in combination with the passenger molecules.

The passenger molecules in the composition are preferably lipophilicsubstances. Passenger molecules that may benefit from enhancedencapsulation include, but are not limited to, cannabinoids, cannabidiol(CBD), tetrahydrocannabinol (THC), menthol, lidocaine, aspirin,ibuprofen, acetaminophen, antifungals, and retinoids. Optionally, thepassenger molecule is one or more cannabinoid. In one embodiment of theinvention, the passenger molecule is cannabidiol (CBD). In oneembodiment of the invention, the passenger molecule istetrahydrocannabinol (THC). In another embodiment of the invention,passenger molecules are a combination of cannabidiol (CBD) andtetrahydrocannabinol (THC).

Load-enhancing surfactants useful for the present invention include, butare not limited to, Polysorbates, PEG esters of hydrogenated castor oil,Polyethylene Glycols, Ethoxylated ether alcohols, Propylene Glycols, PPGesters, Sodium, Potassium or Ammonium Salts of Fatty Acids, andderivatives or combinations thereof. Optionally, the load-enhancingcompound is one or more polysorbate and derivatives, PEG esters ofhydrogenated castor oil and derivatives, or combination thereof.Optionally, the load enhancing compounds are PEG-40 hydrogenated castoroil and derivatives, Polysorbate (Tween) 20 and derivatives, Polysorbate(Tween) 80, and derivatives, or combinations thereof. In one embodimentof the invention, the load-enhancing compound is a PEG ester ofhydrogenated castor oil. In one embodiment of the invention, theload-enhancing compound is PEG 40 hydrogenated castor oil. In oneembodiment, the load-enhancing compound is Polysorbate (Tween) 20. Inone embodiment, the load-enhancing compound is Polysorbate (Tween) 80.In one embodiment, the load-enhancing compound is a combination of PEG40 hydrogenated castor oil and Polysorbate (Tween) 20 or Polysorbate(Tween) 80.

The Surfactant-Enhanced Phospholipid Vesicles (SEPV) compositionoptionally has 1%-50% (w/w) phospholipid stock solution, 10%-90% (w/w)ethanol, 1%-50% (w/w) passenger substance; and 1-50% (w/w) surfactant.Optionally, the composition has 10%-30% (w/w) phospholipid stocksolution, 50%-75% (w/w) ethanol, 1%-20% (w/w) passenger substance; and0.1%-25% (w/w) surfactant. Optionally, the composition has 14%-25.5%(w/w) phospholipid stock solution, 56%-69.6% (w/w) ethanol, 5%-10% (w/w)passenger substance; and 0.5%-20% (w/w) surfactant. In one embodiment ofthe invention, the composition has 14.00% (w/w) phospholipid stocksolution, 56.00% (w/w) ethanol, 10.0% (w/w) passenger substance; and20.00% (w/w) surfactant. In one embodiment of the invention, thecomposition has 25.5% (w/w) phospholipid stock solution, 69.0% (w/w)ethanol, 5.0% (w/w) passenger substance; and 0.5% (w/w) surfactant. Inone embodiment of the invention, the composition has 24.0% (w/w)phospholipid stock solution, 69.60% (w/w) ethanol, 5.0% (w/w) passengersubstance; and 1.4% (w/w) surfactant. Optionally, water can be used todilute the finished encapsulate to achieve the desired passengerconcentration. Optionally, water can be used to dilute the finishedencapsulate at 1:1 up to 1:1000. Optionally, water can be used to dilutethe finished composition at 1:10 up to 1:100.

Method of Making a Surfactant-Enhanced Phospholipid Vesicle Composition

A method of encapsulating passenger molecule compounds inSurfactant-Enhanced Phospholipid Vesicles (SEPV) is disclosed. Thephospholipid stock for preparing the SEPV is manipulated by dilutionwith an ethanol solvent, combined with one or more desired passenger andthen mixed with a load-enhancing surfactant to form a passengerencapsulate of SEPV. Optionally, the passenger encapsulate is for oraldelivery. Optionally, the passenger encapsulate is for transdermaldelivery. The passenger encapsulate may then be combined with additionalingredients to enhance flavor, appearance or usability of thepreparation and may be diluted to achieve the desired dose for oralmucosa delivery or beverage delivery.

A method of encapsulating cannabinoid passenger molecules inSurfactant-Enhanced Phospholipid Vesicles (SEPV) is disclosed. Thephospholipid stock for preparing the SEPV is manipulated by dilutionwith an ethanol solvent, combined with one or more desired cannabinoidpassenger and then mixed with a load-enhancing surfactant to form acannabinoid encapsulate of SEPV. Optionally, the cannabinoid encapsulateis for oral or transmucosal delivery. Optionally, the cannabinoidencapsulate of is for topical or transdermal delivery. The cannabinoidpassenger encapsulate may then be combined with additional ingredientsto enhance flavor, appearance or usability of the preparation.Optionally, the cannabinoid preparation is diluted to achieve thedesired dose for oral or transmucosal or beverage delivery, or thedesired dose for topical or transdermal delivery.

To make the Surfactant-Enhanced Phospholipid Vesicles (SEPV), aphospholipid stock solution is combined with an ethanol diluent andmixed until homogenous. The cannabinoid passenger substance is added tothe ethanol-phospholipid mixture and blended until the cannabinoidpassenger-stock mixture is homogenous with the cannabinoid passengerfully incorporated. A quantity of load-enhancing surfactant is thenthoroughly combined with the cannabinoid passenger-stock mixtureyielding a cannabinoid encapsulate of surfactant-enhanced phospholipidvesicles with cannabinoid passenger molecules encapsulated therein. Thecannabinoid encapsulate may then be combined with additional ingredientsto enhance flavor, appearance or usability of the preparation and may bediluted to achieve the desired dose for oral or transmucosal or beveragedelivery, or the desired dose for topical or transdermal delivery.

The phospholipid stock used to make the Surfactant-Enhanced PhospholipidVesicles (SEPV), is prepared by combining phospholipids with ethanol andstirring at ambient room temperature until dissolved. Optionally, theethanol used in the phospholipid stock is dehydrated 190 proof ethanol.A small quantity of water having a pH of 5-8 is added to theethanol/phospholipid mixture and stirred until an optically clearphospholipid stock solution results. The ratio of the components in thephospholipid stock solution ranges from 75-89% ethanol, 10-20%phospholipids and 1-5% (w/w) water. Optionally, the ratio of componentsin the phospholipid stock is 80% ethanol/17.75% phospholipids/2.25%water (w/w). Optionally, the phospholipids are derived from soylecithin. Phospholipids are selected from phosphatidylcholine (PC),phosphatidylethanolamine (PE), phosphatidic acid (PA) andphosphatidylinositol (PI), and mixtures thereof. Optionally,phosphatidylcholine (PC) comprises at least 50% by weight of thephospholipid mixture. Optionally, phosphatidylcholine comprises 65% ofthe phospholipid total.

The phospholipid stock mixture is then combined with a quantity ofethanol, 1:1 to 1:100 (by volume) and stirred until the mixture ishomogenous. Passenger molecules are added to the ethanol-dilutedphospholipid stock mixture and mixed until the passenger is fullyincorporated and the passenger-stock mixture is homogenous. Thepassenger-stock mixture is then combined with a quantity of surfactant,1:1 to 1:100 (by volume) and mixed until a uniform composition having anopalescent appearance is achieved. The resulting composition hasnano-sized surfactant-enhanced phospholipid vesicles sized from 25 nm to200 nm in diameter. Optionally, the vesicles are sized from 80 nm to 130nm. Optionally, the vesicles are about 80 nm in diameter.

Surfactants are used in the present invention as load-enhancingcompounds that increase the concentration of one or more passengermolecule loaded into a phospholipid based nano-sized vesicle toconcentrations greater than could be achieved without the enhancer andalso maintains the structural integrity of the vesicles preventingprecipitation of the encapsulated passenger. Load-enhancing surfactantsuseful for the present invention include, but are not limited to,Polysorbates, PEG esters of hydrogenated castor oil, PolyethyleneGlycols, Ethoxylated ether alcohols, Propylene Glycols, PPG esters,Sodium, Potassium or Ammonium Salts of Fatty Acids, and derivatives orcombinations thereof. Optionally, the load-enhancing compound is one ormore of polysorbate and derivatives, PEG esters of hydrogenated castoroil and derivatives, or combinations thereof. Optionally, the loadenhancing compounds are PEG-40 hydrogenated castor oil and derivatives,Polysorbate (Tween) 20 and derivatives, Polysorbate (Tween) 80 andderivatives, or combinations thereof. In one embodiment of theinvention, the load-enhancing compound is a PEG ester of hydrogenatedcastor oil. In one embodiment of the invention, the load-enhancingcompound is PEG 40 hydrogenated castor oil. In one embodiment, theload-enhancing compound is Polysorbate (Tween) 20. In one embodiment,the load-enhancing compound is Polysorbate (Tween) 80. In oneembodiment, the load-enhancing compound is a combination of PEG 40hydrogenated castor oil and Polysorbate (Tween) 20 or Polysorbate(Tween) 80.

Passengers Substances

Passenger that may be encapsulated in surfactant-enhanced phospholipidvesicles are preferably lipophilic substances. Passenger molecules thatmay benefit from enhanced encapsulation include, but are not limited to,cannabinoids, cannabidiol (CBD), tetrahydrocannabinol (THC), menthol,lidocaine, aspirin, ibuprofen, acetaminophen, antifungals, andretinoids. Optionally, the passenger is one or more cannabinoid. In oneembodiment of the invention, the passenger molecule is cannabidiol(CBD). In one embodiment of the invention, the passenger molecule istetrahydrocannabinol (THC). In another embodiment of the invention,passenger molecules are a combination of cannabidiol (CBD) andtetrahydrocannabinol (THC).

In one embodiment of the invention, the passenger molecule is a Cannabissativa-derived compound. Cannabis sativa-derived substances can bederived from all varieties of Cannabis sativa, including hemp. In oneembodiment of the invention, the passenger molecule is a Cannabisindica-derived compound. Organic solvents, such as ethanol, butane, andpropane, can be used to extract Cannabis-derived substances, includingcannabidiol (CBD), tetrahydrocannabinol (THC), flavonoids and terpenes.Cannabidiol (CBD) can also be extracted from hemp plant materials by asupercritical carbon dioxide extraction process, wherein phase changesinduced in the CO₂, utilizing temperature and pressure, yield extractsfree of toxic solvents. Cannabis varieties used for hemp production areone preferred source of CBD because of a high concentration of CBD witha low concentration of THC in materials from those plants.

Cannabis sativa has over 483 known compounds, over 60 of which areclassified as cannabinoids, many of which have mental and physicaleffects, which may be used in the present invention, includingtetrahydrocannabinol (THC) and cannabidiol (CBD). Cannabidiol (CBD) isone of the most prevalent chemical compounds in the cannabis plant andtypically does not produce psychotropic effects. Cannabis sativa-derivedcompounds also include numerous non-cannabinoid compounds. Optionally,the composition of surfactant-enhanced phospholipid vesicles has one ormore cannabinoid passenger. Optionally, the composition ofsurfactant-enhanced phospholipid vesicles has one or morenon-cannabinoid passenger. Optionally, the composition ofsurfactant-enhanced phospholipid vesicles has one or more cannabinoidpassenger and one or more non-cannabinoid passenger.

In one embodiment of the invention, the passenger molecule is anon-cannabinoid Cannabis-derived compound. Among the non-cannabinoidcannabis-derived compounds are a variety of terpenes and flavonoids.Terpenes are oils secreted from the plant which give the plant itscharacteristic odor and produce physical effects similar to those seenwith CBD. Flavonoids are phytonutrients that are pharmacologicallyactive having individual medicinal benefits and enhancing the effects ofother cannabis-derived compounds. Flavonoids and terpenes may be addedto the preparations in addition to the cannabinoids to improve theuptake, or enhance or regulate the effects of one or more of thecannabinoid active ingredients. Optionally, the composition ofsurfactant-enhanced phospholipid vesicles has one terpene or flavonoidnon-cannabinoid compound encapsulated therein.

Cannabinoids other than CBD and THC can be derived from Cannabis sativaand Cannabis indica and may also be used as passenger molecules in thedisclosed invention. Most of the other cannabinoids are non-psychoactiveor mildly psychoactive, and have physiological effects similar to theeffects seen for CBD. These other cannabinoids may work synergisticallyto enhance the effects of CBD and THC. Other cannabinoids that may beused as passenger molecules in the disclosed invention include, but arenot limited to: Cannabigerol (CBG), Cannabidiolic Acid (CBDA),Tetrahydrocannabinolic Acid (THCA), Cannabinol (CBN), Cannabichromene(CBC), Cannabicyclol (CBL), Cannabivarin (CBV), Tetrahydrocannabivarin(THCV), Cannabidivarin (CBDV), Cannabichromevarin (CBCV),Cannabigerovarin (CBGV), Cannabigerol monomethyl ether (CBGM),Cannabielsoin (CBE), Cannabicitran (CBT), and combinations thereof.Synthetically-derived cannabinoids may also be used as passengermolecules.

Whole plant extracts of Cannabis spp. may also be used as passengermolecules in the disclosed invention, and may be beneficial becausenon-cannabinoid plant compounds, such as the terpenes and flavonoids,are present in a whole plant sample. Whole plant cannabis extracts canalso be encapsulated in the surfactant-enhanced phospholipid vesicles.Whole plant cannabis extract is an oily or waxy material that is solublein lipids and alcohols. Whole plant extracts will vary in the amount ofcannabinoids in the extract depending on whether the extract is preparedfrom marijuana-grade cannabis or industrial-grade hemp. Both types ofwhole plant extracts will have cannabinoids, terpenes and flavonoids,with the primary difference being the concentrations of CBD and THC inthe final extract.

CBD and THC extracts can be advantageously used in combination aspassengers in the surfactant-enhanced phospholipid vesicle composition.CBD and THC are extracted from cannabis plants as separate isolates,either as oils or crystals, or optionally, are synthetically-derived,and then combinations of these extracts can be encapsulated in thesurfactant-enhanced phospholipid vesicles. The CBD and THC can becombined and encapsulated in the surfactant-enhanced phospholipidvesicle composition in the same step, or the CBD and THC can beindividually encapsulated in surfactant-enhanced phospholipid vesiclesand then combined into a single composition.

Oral delivery means that may be used in the disclosed invention include,but are not limited to: liquids, as drops, sprays, aerosols, or shots,gels, pastes, lozenges, gums, gummy candies, hard candies, orallydissolving strips, tablets, and swish and swallow preparations. Thepreparation may be applied under the tongue (sublingual), inside thecheeks (buccal), or inside the oral cavity. Oral delivery means may alsoinclude preparations that may be consumed as a beverage type deliverymeans, such as a drinkable beverage, shot, or swish and swallow typepreparation.

Preparations for oral delivery may also incorporate additionalnon-cannabis compounds, such as sweeteners including nutritive andnon-nutritive sweeteners, flavoring agents, vitamins, minerals, herbalingredients, distillates, and/or extracts, fruit and vegetableingredients and/or extracts, amino acids, nutraceutical ingredients; andcombinations thereof, which may improve functionality of the cannabinoidencapsulate or provide additional benefits to the user. Examples ofingredients that may be used advantageously for an oral preparationinclude, but are not limited to: stevia extract, sugar, yerba mate,green coffee bean extract, monk fruit extract, citric acid, potassiumsorbate, black pepper extract, lemon extract, ginger, tulsi distillate,turmeric, theanine, xanthan gum, and glycerin. Preparations for oraldelivery may also include excipient ingredients to improve appearance,application, taste, smell, longevity, stabilization, or adherence of thepreparation.

Preparations for oral delivery are made by combining a phospholipidstock having ethanol, phospholipids and water, with an ethanol diluent,and mixed until homogenous. Phospholipids include phospholipids derivedfrom lecithin. One or more cannabis-derived passenger is added to thecombined ethanol-stock mixture and blended until the passenger-stockmixture is homogenous and the cannabis-derived passenger is fullysolubilized. The load-enhancing surfactant compound is added to thepassenger-stock mixture and blended until a homogenous mixture ofsurfactant-enhanced phospholipid vesicles having encapsulated cannabisderived passenger encapsulated therein is achieved.

Cannabinoids encapsulated in surfactant-enhanced phospholipid vesicles(SEPV) for oral delivery is disclosed. The surfactant-enhancedphospholipid vesicles are formulated for delivery of the cannabinoidcompounds to the oral cavity or mucosa of a subject. Optionally, theoral preparation is for application of the SEPV composition to the oral,sublingual or buccal mucosa of a subject. Optionally, the SEPVcomposition is applied to the oral cavity as liquid drops, sprays,aerosols, or shots, gels, pastes, lozenges, gums, gummy candies, hardcandies, orally dissolving strips, tablets, and swish and swallowpreparations. These types of preparations are held in the mouth, underthe tongue, or allowed to disintegrate for up to several minutes priorto swallowing. Optionally, the oral delivery is as a liquid preparationin a drinkable format, such as a beverage, shot, or swish and swallowpreparation. Optionally, the liquid preparation is a drinkable format,such as a beverage (typically more than 1.5 ounce), or as a shot(typically 1.5 ounce or less), or swish and swallow preparation(typically 1.0 ounce or less).

Cannabinoids encapsulated in surfactant-enhanced phospholipid vesiclesfor topical or transdermal delivery is disclosed. Thesurfactant-enhanced phospholipid vesicles are formulated for delivery ofthe cannabis-derived compounds to an epidermal area of a subject.Optionally, the delivery route is topical or transdermal via a topicallyapplied preparation, such as a topically applied cream, lotion,ointment, wax, topically applied spray, gel, balm, transdermal patch, orother transdermal application means to an epidermal area.

Method of Using

Methods of using surfactant-enhanced phospholipid vesicles withencapsulated passenger molecules is disclosed. Methods for deliverycomprise providing a passenger encapsulate having one or more passengermolecules encapsulated in surfactant-enhanced phospholipid vesiclescapable of delivering the passenger compound to a subject, preparing thepassenger encapsulate for delivery by mixing the passenger encapsulatewith diluents or other constituents to reach the desired dosage ofpassenger compound, and administering the passenger encapsulatepreparation to a subject. Optionally, the route of delivery is oral, viaa transmucosal preparation, a sublingual preparation, a buccalpreparation, or an oral beverage preparation. Optionally, the deliveryroute is topical or transdermal via a topically applied preparationmeans to an epidermal area. Passenger molecules in the passengerencapsulate are preferably lipophilic substances. Passenger moleculesthat may benefit from enhanced encapsulation include, but are notlimited to, cannabinoids, cannabidiol (CBD), tetrahydrocannabinol (THC),menthol, lidocaine, aspirin, ibuprofen, acetaminophen, antifungals, andretinoids.

Optionally, the passenger encapsulate is applied to the oral cavity asliquid drops, sprays, aerosols, or shots, gels, pastes, lozenges, gums,gummy candies, hard candies, orally dissolving strips, tablets, andswish and swallow preparations. These types of preparations are held inthe mouth, under the tongue or allowed to disintegrate for up to severalminutes prior to swallowing. Optionally, the oral delivery is as aliquid preparation in a drinkable format, such as a beverage, shot, orswish and swallow preparation. Optionally, the liquid preparation is adrinkable format, such as a beverage (typically more than 1.5 ounce) oras a shot (typically 1.5 ounce or less), or swish and swallowpreparation (typically 1.0 ounce or less).

Optionally, the delivery route for the passenger encapsulate istransdermal via a topically applied preparation, such as a topicallyapplied cream, lotion, ointment, wax, topically applied spray, gel,balm, transdermal patch or other transdermal application means to anepidermal area.

Methods of using surfactant-enhanced phospholipid vesicles withencapsulated cannabinoid passenger molecules is disclosed. Methods fordelivery comprise providing a cannabinoid encapsulate having one or morecannabinoid passenger molecules encapsulated in surfactant-enhancedphospholipid vesicles capable of delivering the cannabinoid to asubject, preparing the cannabinoid encapsulate for delivery by mixingthe cannabinoid encapsulate with diluents, excipients, or otherconstituents to reach the desired dosage of cannabinoid compound, andadministering the cannabinoid encapsulate preparation to a subject.

Optionally, the passenger is one or more cannabinoid. Optionally, thepassenger is one or more Cannabis-derived substance. Optionally, thecannabinoids are synthetically-derived. In one embodiment of theinvention, the passenger molecule is cannabidiol (CBD). In oneembodiment of the invention, the passenger molecule istetrahydrocannabinol (THC). In another embodiment of the invention,passenger molecules are a combination of cannabidiol (CBD) andtetrahydrocannabinol (THC).

Optionally, the route of delivery for the cannabinoid encapsulate isoral, via a transmucosal preparation, a sublingual preparation, a buccalpreparation, or an oral beverage preparation. These types ofpreparations may be held in the mouth, under the tongue or allowed todisintegrate for up to several minutes prior to swallowing. Optionally,the oral delivery is as a liquid preparation in a drinkable format, suchas a beverage, shot, or swish and swallow preparation. Optionally, theliquid preparation is a drinkable format, such as a beverage (typicallymore than 1.5 ounce) or as a shot (typically 1.5 ounce or less), orswish and swallow preparation (typically 1.0 ounce or less).

Optionally, the delivery route for the cannabinoid encapsulate istopical or transdermal via a topically applied preparation, such as atopically applied cream, lotion, ointment, wax, topically applied spray,gel, balm, transdermal patch, or other transdermal application means toan epidermal area.

Cannabinoid substances can be administered in dosages ranging up to 1200mg per day. Cannabinoid encapsulates have a Cannabis sativa-derivedsubstance concentration of 3 mg/mL to 300 mg/mL. Cannabis sativa-derivedsubstances which are encapsulated in surfactant-enhanced phospholipidvesicles are administered in dosages ranging up from 1 mg to 300 mg perday in single or divided doses or any dose between 1 mg and 300 mg perday. Optionally, dosages range from 1 mg to 100 mg per day in single ordivided doses. Optionally, dosages range from 10 mg to 100 mg per day insingle or divided doses. Optionally, the dosages range from 1 mg to 20mg per day in a single or divided dose.

Cannabinoid encapsulated in surfactant-enhanced phospholipid vesiclesfor oral delivery is disclosed. The surfactant-enhanced phospholipidvesicles are formulated for delivery of the cannabis-derived compoundsto the oral cavity or oral mucosa of a subject. Optionally, the oraldelivery is application of the cannabinoid encapsulate to the oral,sublingual or buccal mucosa of a subject. Optionally, the cannabinoidencapsulate is applied to the oral cavity as liquid drops, sprays,aerosols, or shots, gels, pastes, lozenges, gums, gummy candies, hardcandies, orally dissolving strips, tablets, and swish and swallowpreparations. These types of preparations are held in the mouth, underthe tongue or allowed to disintegrate for up to several minutes prior toswallowing. Optionally, the oral delivery is as a liquid preparation ina drinkable format, such as a beverage, shot, or swish and swallowpreparation. Optionally, the liquid preparation is a drinkable format,such as a beverage (typically more than 1.5 ounce) or as a shot(typically 1.5 ounce or less), or swish and swallow preparation(typically 1.0 ounce or less).

In one embodiment, a phospholipid stock having phospholipids, ethanoland water is combined with an ethanol diluent and blended untilhomogenous. Crystalline CBD having greater than 99% purity is combinedwith the ethanol-phospholipid stock until the CBD passenger-stockmixture is homogenous and the CBD is uniformly distributed therein. Aquantity of load-enhancing surfactant is combined with the CBDpassenger-stock mixture and blended until a homogenous cannabinoidencapsulate of surfactant-enhanced phospholipid vesicles with CBDencapsulated therein is achieved. Phospholipids used in the phospholipidstock are optionally derived from lecithin. Phospholipids used in thephospholipid stock are optionally derived from soy lecithin. The CBDcannabinoid encapsulate may then be combined or diluted with an aqueousor non-aqueous delivery system without disruption of thesurfactant-enhanced phospholipid vesicles.

Examples

An exemplary composition is detailed in Table 1, below. Examples shownherein are not meant to limit the combinations or concentrations ofcomponents for the composition for the present invention, but are merelyrepresentative ways in which the components may be used. The examplecomposition has been shown to provide greater physical stability thanpredecessor compositions as evidenced by no crystallization after morethan three months ambient room temperature storage. The loadingenhancement herein can be applied to all forms of delivery vehicles,inclusive of, but not limited to, topical, oral, mucosal, vaginal,rectal, beverage, parenteral, and inhalation. Load enhancing compoundsinclude but are not limited to Polysorbates, PEG esters of hydrogenatedcastor oil, Polyethylene Glycols, Ethoxylated ether alcohols, PropyleneGlycols, PPG esters, Sodium, Potassium or Ammonium Salts of Fatty Acids,and derivatives thereof, etc. In one embodiment of the invention, theload-enhancing compound is a PEG ester of hydrogenated castor oil. Inone embodiment of the invention, the load-enhancing compound is PEG-40hydrogenated castor oil. In one embodiment of the invention, theload-enhancing compound is Polysorbate (Tween) 20. In one embodiment ofthe invention, the load-enhancing compound is Polysorbate (Tween) 80. Inone embodiment of the invention, the load-enhancing compound is acombination of PEG-40 hydrogenated castor oil and Polysorbate (Tween) 20or Polysorbate (Tween) 80.

TABLE 1 Passenger Molecule Loading Enhancing Composition PercentageIngredient (v/v) NLP Range Purpose PL Stock (Lecithin, ~1-50% ~1-20Encapsulation Ethanol, Water) Ethanol ~10-90%  ~1-90 Diluent Passenger~1-50% Not claimed Delivered molecule Molecule¹ Loading ~1-80% Notclaimed Passenger loading Enhancer² Enhancement Water ~1-99.9%  Diluentfor finished composition ¹Passenger molecule examples include but arenot limited to cannabinoids, cannabidiol, tetrahydrocannabinol, menthol,lidocaine, aspirin, ibuprofen, acetaminophen, antifungals, retinoids.²Load enhancing compounds include but are not limited to Polysorbates,PEG esters of hydrogenated castor oil, Polyethylene Glycols,Sodium/Potassium/Ammonium Salts of Fatty Acids and derivatives, etc.

The examples below are illustrative examples that are envisioned for thedisclosed invention and are not intended to be the only examples,embodiments, formulations, compositions, or concentrations that may beused with the disclosed invention.

EXAMPLE 1 Illustrative Solubilized CBD in the Cannabinoid EncapsulateProduct Name: 100 mg/g CBD Concentrate Batch Size 150.00 Phase/DZ #Ingredient INCI Name % Wt. A DZ4130 Phospholipid Alcohol, Lecithin,14.00 21.00 Stock Water A DZ2330 Ethanol Alcohol 56.00 84.00 A DZ4730Cannabidiol Cannabidiol 10.00 15.00 A DZ4800 PEG-40 PEG-40 20.00 30.00Hydrogenated Hydrogenated Castor Oil Castor Oil 100.00 150.00 StepsProcedure: 1 In a suitable vessel, add the phospholipid stock andethanol. Mix together for 5-10 mins. 2 Add CBD to mixing solution. Allowto mix for 15-20 mins or until all CBD has fully dissolved. 3 Oncesolution is homogenous. Add PEG-40 Hydrogenated Castor Oil. Allow to mixfor 15-20 minutes or until homogenous. 4 Dilute an aliquot of finalproduct 1:1000 and test for PSA.

The table below is an illustrative example of component concentrationshown in descending order for a sample of passenger encapsulate preparedaccording to the present invention. The top section of the chart showsthe solvent broken down by the percentage of ethanol solvent in thephospholipid stock solution and the percentage of ethanol solvent usedas a diluent prior to incorporating the passenger into the phospholipidstock. The bottom section of the table shows the combined concentrationsin descending order for a representative sample of a CBD passengerencapsulate.

EXAMPLE 2 Illustrative Product Composition in the CannabinoidEncapsulate Component INCI Name % in Product % Breakdown Solvent(diluent) Alcohol 56.00 56.00 Surfactant PEG-40 20.00 20.00 HydrogenatedCastor Oil Solvent (stock) Alcohol 14.00 11.26 Passenger Cannabidiol10.00 10.00 Phospholipid (stock) Lecithin 2.42 Water (stock) Water 0.32Final Breakdown Final % Breakdown Alcohol 67.26 PEG-40 HydrogenatedCastor Oil 20.00 Cannabidiol 10.00 Lecithin 2.42 Water 0.32 100.00

The chart below illustrates several possible examples of oralpreparations that may be prepared using a passenger encapsulate preparedaccording to the present invention. The passenger encapsulate used inthese examples is a THC encapsulate having about 5% THC that is dilutedto around 0.5% prior to use in the final preparation.

EXAMPLE 3 Illustrative Oral Preparations using the CannabinoidEncapsulate Batch 3 Batch 1 Batch 2 Chill #2 Energy #2 Composition Water98.162 96.81 70.00 QS Sugar 7.00 7.00 Stevia Extract 0.25 Yerba Mate0.55 Green Coffee Bean 0.085 Monk Fruit Extract 50% 0.01 0.01 CitricAcid 0.67 0.67 0.45 0.18 Potassium Sorbate 0.10 0.10 0.10 0.10 Blackpepper Extract 0.02 Lemon Extract 0.10 Ginger 0.07 0.07 Tulsi Distillate0.10 Turmeric Powder 0.25 Theanine 0.10 Water 2.50 EtOH 0.3574 0.02 EtOHStock 0.26 0.10 Xanthan Gum 0.05 0.15 0.20 0.10 Glycerin 0.50 1.50 1.501.50 IHC Encapsulate 0.5179 0.516 0.442 0.442 (adjusted for potency ofTHC) THC Encapsulate THC 5.00 5.00 5.00 5.00 EtOH 69.00 69.00 69.0069.00 EtOH Stock 25.50 25.50 25.50 25.50 PEG-40 Hydrogenated 0.50 0.500.50 0.50 Castor Oil Polysorbate 20 0.40 0.40 0.40 QS Water

The illustrative oral preparations in Example 3 are examples where thecomposition of Surfactant-Enhanced Phospholipid Vesicles with a THCpassenger incorporated within the vesicles is combined with additionalingredients suitable for oral delivery of the passenger substance in aformat, such as a beverage (volume variable) or a shot (about 1 ounce).In the example preparation, a composition of THC encapsulate havingabout 5.00% THC is prepared according the present invention thencombined with additional ingredients, and diluted with water to adesired final volume having the desired final THC concentration.

Preparations for oral delivery as a beverage or shot may include avariety of desired ingredients, such as sweeteners, flavoring agents,vitamins, minerals, herbal ingredients, fruit or vegetable extracts,herb or spice extracts, caffeine, amino acids, and nutraceuticalingredients, as well as excipient ingredients to improve appearance,application, adherence, dilution, stability, or longevity of thepreparation. Examples of ingredients that may be used advantageously foran oral preparation include, but are not limited to: stevia extract,sugar, yerba mate, green coffee bean extract, monk fruit extract, citricacid, potassium sorbate, black pepper extract, lemon extract, ginger,tulsi distillate, turmeric, theanine, xanthan gum, and glycerin.

The examples showing compositions with enhanced loading, productcompositions and oral preparations presented herein are representativeexamples only. The method of the invention is applicable to other typesof passenger substances and these examples are not meant to constitutethe entire range of passenger substances or load-enhancing compositions,product compositions or oral preparations that may be used in the methoddisclosed herein.

1. A method for administering a cannabinoid substance in an oraldelivery protocol comprising the steps of: providing a cannabinoidencapsulate having one or more cannabinoid substance encapsulated in oneor more surfactant-enhanced phospholipid vesicles having phospholipids,ethanol, water, and one or more surfactant selected from Polysorbatesand derivatives, PEG esters of hydrogenated castor oil and derivatives,and combinations thereof, wherein said cannabinoid substance in saidcannabinoid encapsulate has a concentration of 3 mg/mL to 300 mg/mL, andsaid cannabinoid encapsulate has less than 2% water (w/w) and up to 25%(w/w) of said surfactant; and administering a quantity of thecannabinoid encapsulate having 1 mg to 100 mg of the cannabinoidsubstance orally to a subject.
 2. The method of claim 1, wherein thecannabinoid substance is selected from cannabidiol (CBD),tetrahydrocannabinol (THC), a whole plant extract of Cannabis sativa, awhole plant extract of Cannabis indica and combinations thereof.
 3. Themethod of claim 2, wherein the cannabinoid substance is cannabidiol(CBD), tetrahydrocannabinol (THC), or a combination of cannabidiol (CBD)and tetrahydrocannabinol (THC).
 4. The method of claim 1, wherein thesurfactant is Polysorbate (Tween) 80, PEG-40 hydrogenated castor oil, orcombinations thereof.
 5. The method of claim 1, wherein the cannabinoidencapsulate is delivered orally as a beverage having from 1.5 ounce to12 ounces.
 6. The method of claim 1, wherein the cannabinoid encapsulateis delivered orally as a shot having 1.5 ounce or less.
 7. The method ofclaim 1, wherein the cannabinoid encapsulate is delivered orally as aswish and swallow preparation having 1.0 ounce or less.
 8. The method ofclaim 7, wherein the swish and swallow preparation remains in contactwith the subject's oral cavity for 30 seconds to 5 minutes.
 9. Themethod of claim 1, further comprising combining said cannabinoidencapsulate with one or more excipient ingredients suitable for an oralpreparation delivered via said beverage, shot, or swish and swallow oralpreparation, said excipient ingredients being for stabilization,appearance, flavoring, or dilution of the oral preparation.
 10. Themethod of claim 1, further comprising combining said cannabinoidencapsulate with one or more sweeteners, flavorings, vitamins, minerals,herbs or herbal extracts, fruit extracts, vegetable extracts, spices orspice extracts, caffeine, amino acids, or nutraceutical ingredientssuitable for delivery in an oral preparation.
 11. The method of claim 1,wherein said cannabinoid substance further comprises Cannabis-derivedterpenes, Cannabis-derived flavonoids, or combinations thereof.
 12. Themethod of claim 1, wherein said cannabinoid substance is a Cannabissativa-derived cannabinoid, Cannabis indica-derived cannabinoid, asynthetically derived cannabinoid, or combinations thereof.
 13. A methodfor intraoral transmucosal administration of a cannabinoid substancecomprising the steps of: providing a cannabinoid encapsulate having oneor more cannabinoid substance encapsulated in one or moresurfactant-enhanced phospholipid vesicle having phospholipids, ethanol,water, and one or more surfactant, wherein the cannabinoid encapsulatehas less than 2% water (w/w), up to 25% (w/w) surfactant, and saidcannabinoid substance in said cannabinoid encapsulate has aconcentration of 3 mg/mL to 300 mg/mL; administering a quantity of thecannabinoid encapsulate having 1 mg to 100 mg of said cannabinoidsubstance to a subject's oral mucosa, and allowing the cannabinoidencapsulate to remain in contact with the oral mucosa for a period oftime ranging from 1 minute to 10 minutes.
 14. The method of claim 13,wherein the surfactant is Polysorbate (Tween) 80, PEG-40 hydrogenatedcastor oil, or combinations thereof.
 15. The method of claim 13, whereinthe cannabinoid encapsulate is kept in contact with the oral mucosa for1 minute to 5 minutes.
 16. The method of claim 13, further comprisingcombining said cannabinoid encapsulate with one or more excipientingredients suitable for preparation of a liquid drop, liquid spray,aerosol, liquid shot, gel, paste, lozenge, gum, gummy candy, hard candy,orally dissolving strip, tablet, or swish and swallow preparation fortransmucosal delivery, said excipient ingredients are for stabilization,appearance, flavoring, dilution, or adherence of the transmucosalpreparation.
 17. The method of claim 13, wherein the cannabinoidencapsulate is applied to the oral mucosa as a liquid drop, liquidspray, aerosol, liquid shot, gel, paste, lozenge, gum, gummy candy, hardcandy, orally dissolving strip, tablet, or swish and swallowpreparation.
 18. The method of claim 13, further comprising combiningsaid cannabinoid encapsulate with one or more sweeteners, flavorings,vitamins, minerals, herbal ingredients and extracts, fruit extracts,vegetable extracts, spices or spice extracts, caffeine, amino acids, andnutraceutical ingredients suitable for delivery via a transmucosalpreparation.
 19. The method of claim 13, wherein said cannabinoidsubstance is a Cannabis sativa-derived cannabinoid, Cannabisindica-derived cannabinoid, a synthetically derived cannabinoid, orcombinations thereof
 20. A method for administration of a cannabinoidsubstance to an epidermal area comprising the steps of: providing acannabinoid encapsulate having one or more cannabinoid substanceencapsulated in one or more surfactant-enhanced phospholipid vesicleshaving phospholipids, ethanol, water, and one or more surfactant,wherein the cannabinoid encapsulate has less than 2% water (w/w), up to25% (w/w) surfactant, and said cannabinoid substance in said cannabinoidencapsulate has a concentration of 3 mg/mL to 300 mg/mL; administering aquantity of the cannabinoid encapsulate having 1 mg to 100 mg ofcannabinoid substance topically to the epidermal area, and allowing thecannabinoid encapsulate to remain in contact the epidermal area for aperiod of time ranging from 1 minute to 24 hours.
 21. The method ofclaim 20, wherein the cannabinoid substance is selected from cannabidiol(CBD), tetrahydrocannabinol (THC), Cannabis-derived terpenes,Cannabis-derived flavonoids, a whole plant extract of Cannabis sativa, awhole plant extract of Cannabis indica and combinations thereof.
 22. Themethod of claim 21, wherein the cannabinoid substance is cannabidiol(CBD), tetrahydrocannabinol (THC), or a combination of cannabidiol (CBD)and tetrahydrocannabinol (THC).
 23. The method of claim 20, wherein thesurfactant is polysorbate (Tween) 80, PEG-40 hydrogenated castor oil, orcombinations thereof.
 24. The method of claim 20, further comprisingcombining the cannabinoid encapsulate with one or more excipientingredient suitable for a topical or transdermal preparation of a cream,lotion, ointment, wax, topically applied spray, gel, balm or transdermalpatch for topical or transdermal administration of the cannabinoidencapsulate, said excipient ingredients are for stabilization,appearance, dilution, or adherence of said topical or transdermalpreparation.
 25. The method of claim 20, wherein the cannabinoidencapsulate is applied to the epidermis in a cream, lotion, ointment,wax, topically applied spray, gel, or balm.
 26. The method of claim 20,wherein the cannabinoid encapsulate is applied to the epidermis in atransdermal patch.
 27. The method of claim 20, wherein said cannabinoidsubstance is a Cannabis sativa-derived cannabinoid, Cannabisindica-derived cannabinoid, a synthetically derived cannabinoid, orcombinations thereof.